Skip to main content
Erschienen in: Strahlentherapie und Onkologie 6/2014

01.06.2014 | Original article

Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma

A PET/CT pilot study using [15O]water and [18F]fluorodeoxyglucose

verfasst von: I. Apostolova, M.D., F. Hofheinz, PhD, R. Buchert, PhD, I.G. Steffen, R. Michel, C. Rosner, V. Prasad, MD, C. Köhler, MD, PhD, T. Derlin, MD, W. Brenner, MD, PhD, S. Marnitz, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

The aim of this pilot study was (1) to evaluate the combination of [18F]fluorodeoxyglucose (FDG) and [15O]water for detection of flow–metabolism mismatch in advanced cervical carcinomas, i.e., increased glycolysis at low blood flow, as a possible parameter for prediction of response to treatment, and (2) to propose a method for automated quantification of its spatial extent.

Patients and methods

The study retrospectively included 10 women with advanced cervical carcinoma in whom PET with both FDG and [15O]water had been performed prior to therapy. The metabolically active tumor volume was delineated automatically in the FDG images. For computation of the regional blood flow in the tumor, a recovery corrected image-derived arterial input function was used. A tumor voxel was classified as mismatched when the voxel SUV of FDG was larger than the median tumor SUV and the voxel perfusion (K1) was smaller than the median perfusion. The absolute mismatch volume (aMMV) was defined as the volume of all mismatched voxels in ml, and the relative mismatch volume (rMMV) as the ratio of the aMMV to the metabolic tumor volume in percent.

Results

The tumors were quite heterogeneous with respect to both FDG uptake and perfusion. The aMMV clustered into 2 groups: “large aMMV” ≥ 10 ml in 40 % of patients and “small aMMV” ≤ 5 ml in 60 % of patients. The rMMV ranged from 12.7–24.9 %. There was no correlation between rMMV and metabolic tumor volume. There was a tendency (p = 0.126) for an association between rMMV and histological grading, rMMV being about 20 % higher in G3 than in G2 tumors. rMMV did not correlate with SUV or perfusion.

Conclusion

These results suggest that combined PET with FDG and [15O]water allows detection and quantitative characterization of flow–metabolism mismatch in advanced cervical carcinomas.
Literatur
1.
Zurück zum Zitat Brihaye C, Depresseux JC, Comar D (1995) Radiation dosimetry for bolus administration of oxygen-15-water. J Nucl Med 36:651–656PubMed Brihaye C, Depresseux JC, Comar D (1995) Radiation dosimetry for bolus administration of oxygen-15-water. J Nucl Med 36:651–656PubMed
2.
Zurück zum Zitat Dunnwald LK, Gralow JR, Ellis GK et al (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457PubMedCentralPubMedCrossRef Dunnwald LK, Gralow JR, Ellis GK et al (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Hansgen G, Kuhnt T, Pigorsch S et al (2002) Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study. Strahlenther Onkol 178:71–77PubMedCrossRef Hansgen G, Kuhnt T, Pigorsch S et al (2002) Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study. Strahlenther Onkol 178:71–77PubMedCrossRef
5.
Zurück zum Zitat Heinzelmann F, Henke G, Grafenstein M von et al (2012) Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer. Strahlenther Onkol 188:568–575PubMedCrossRef Heinzelmann F, Henke G, Grafenstein M von et al (2012) Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer. Strahlenther Onkol 188:568–575PubMedCrossRef
6.
Zurück zum Zitat Hofheinz F, Langner J, Petr J et al (2012) A method for model-free partial volume correction in oncological PET. EJNMMI Res 2 Hofheinz F, Langner J, Petr J et al (2012) A method for model-free partial volume correction in oncological PET. EJNMMI Res 2
7.
Zurück zum Zitat Hofheinz F, Pötzsch C, Oehme L et al (2012) Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin 51:9–16PubMedCrossRef Hofheinz F, Pötzsch C, Oehme L et al (2012) Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin 51:9–16PubMedCrossRef
8.
Zurück zum Zitat Kimura H, Braun RD, Ong ET et al (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522–5528PubMed Kimura H, Braun RD, Ong ET et al (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522–5528PubMed
9.
Zurück zum Zitat Klopp AH, Eifel PJ (2012) Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol 22:143–150PubMedCrossRef Klopp AH, Eifel PJ (2012) Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol 22:143–150PubMedCrossRef
10.
Zurück zum Zitat Komar G, Kauhanen S, Liukko K et al (2009) Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 15:5511–5517PubMedCrossRef Komar G, Kauhanen S, Liukko K et al (2009) Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 15:5511–5517PubMedCrossRef
11.
Zurück zum Zitat Kunz-Schughart LA, Mueller-Klieser W, Vaupel P (2012) Tumor pathophysiology. Strahlenther Onkol 188(Suppl 3):299–303PubMedCrossRef Kunz-Schughart LA, Mueller-Klieser W, Vaupel P (2012) Tumor pathophysiology. Strahlenther Onkol 188(Suppl 3):299–303PubMedCrossRef
12.
Zurück zum Zitat Lin A, Hahn SM (2012) Hypoxia imaging markers and applications for radiation treatment planning. Semin Nucl Med 42:343–352PubMedCrossRef Lin A, Hahn SM (2012) Hypoxia imaging markers and applications for radiation treatment planning. Semin Nucl Med 42:343–352PubMedCrossRef
13.
Zurück zum Zitat Ma DJ, Zhu JM, Grigsby PW (2011) Change in T2-fat saturation MRI correlates with outcome in cervical cancer patients. Int J Radiat Oncol Biol Phys 81:e707–e712 Ma DJ, Zhu JM, Grigsby PW (2011) Change in T2-fat saturation MRI correlates with outcome in cervical cancer patients. Int J Radiat Oncol Biol Phys 81:e707–e712
14.
Zurück zum Zitat Mankoff DA, Dunnwald LK, Partridge SC, Specht JM (2009) Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res 15:5294–5296PubMedCentralPubMedCrossRef Mankoff DA, Dunnwald LK, Partridge SC, Specht JM (2009) Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res 15:5294–5296PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Marnitz S, Stromberger C, Kawgan-Kagan M et al (2010) Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol 186:572–579PubMedCrossRef Marnitz S, Stromberger C, Kawgan-Kagan M et al (2010) Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol 186:572–579PubMedCrossRef
17.
Zurück zum Zitat Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115:3166–3180PubMedCrossRef Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115:3166–3180PubMedCrossRef
18.
Zurück zum Zitat Olsen JR, Dehdashti F, Siegel BA et al (2011) Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET. Int J Radiat Oncol Biol Phys 81:772–777PubMedCrossRef Olsen JR, Dehdashti F, Siegel BA et al (2011) Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET. Int J Radiat Oncol Biol Phys 81:772–777PubMedCrossRef
19.
Zurück zum Zitat Quinn MA, Benedet JL, Odicino F et al (2006) Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S43–S103PubMedCrossRef Quinn MA, Benedet JL, Odicino F et al (2006) Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S43–S103PubMedCrossRef
20.
Zurück zum Zitat Roberts C, Liyanage SH, Harry VN, Rockall AG (2011) Functional imaging for assessing tumor response in cancer of the cervix. Womens Health (Lond Engl) 7:487–497 Roberts C, Liyanage SH, Harry VN, Rockall AG (2011) Functional imaging for assessing tumor response in cancer of the cervix. Womens Health (Lond Engl) 7:487–497
21.
Zurück zum Zitat Schuetz M, Schmid MP, Potter R et al (2010) Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 49:941–947PubMedCrossRef Schuetz M, Schmid MP, Potter R et al (2010) Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 49:941–947PubMedCrossRef
22.
Zurück zum Zitat Siva S, Herschtal A, Thomas JM et al (2011) Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 117:3981–3988PubMedCrossRef Siva S, Herschtal A, Thomas JM et al (2011) Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 117:3981–3988PubMedCrossRef
23.
Zurück zum Zitat Strauss HG, Kuhnt T, Laban C et al (2002) Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol 178:378–385PubMedCrossRef Strauss HG, Kuhnt T, Laban C et al (2002) Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol 178:378–385PubMedCrossRef
24.
Zurück zum Zitat Surti S, Kuhn A, Werner ME et al (2007) Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 48:471–480PubMed Surti S, Kuhn A, Werner ME et al (2007) Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 48:471–480PubMed
25.
Zurück zum Zitat Veldt AA van der, Hendrikse NH, Harms HJ et al (2010) Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 51:1684–1690PubMedCrossRef Veldt AA van der, Hendrikse NH, Harms HJ et al (2010) Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 51:1684–1690PubMedCrossRef
26.
Zurück zum Zitat Wouters BG, Brown JM (1997) Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat Res 147:541–550PubMedCrossRef Wouters BG, Brown JM (1997) Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat Res 147:541–550PubMedCrossRef
27.
Zurück zum Zitat Zhang Y, Chen JY, Xie CM et al (2011) Diffusion-weighted magnetic resonance imaging for prediction of response of advanced cervical cancer to chemoradiation. J Comput Assist Tomogr 35:102–107PubMedCrossRef Zhang Y, Chen JY, Xie CM et al (2011) Diffusion-weighted magnetic resonance imaging for prediction of response of advanced cervical cancer to chemoradiation. J Comput Assist Tomogr 35:102–107PubMedCrossRef
28.
Zurück zum Zitat Zips D, Boke S, Kroeber T et al (2011) Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol 187:306–310PubMedCrossRef Zips D, Boke S, Kroeber T et al (2011) Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol 187:306–310PubMedCrossRef
Metadaten
Titel
Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma
A PET/CT pilot study using [15O]water and [18F]fluorodeoxyglucose
verfasst von
I. Apostolova, M.D.
F. Hofheinz, PhD
R. Buchert, PhD
I.G. Steffen
R. Michel
C. Rosner
V. Prasad, MD
C. Köhler, MD, PhD
T. Derlin, MD
W. Brenner, MD, PhD
S. Marnitz, MD, PhD
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 6/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0611-7

Weitere Artikel der Ausgabe 6/2014

Strahlentherapie und Onkologie 6/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.